Dimeric acetylcholinesterase (AChE) inhibitors containing a single 9-amino-1,2,3,4-tetrahydroacridine (tacrine) unit were constructed in an effort to further delineate structural requirements for optimal binding to the AChE peripheral site. Basic amines of differing hydrophobicity were selected as peripheral site ligands, and in each case, improvements in inhibitory potency and selectivity were seen relative to tacrine itself. AChE IC50 values of the optimum dimers decrease significantly as the peripheral site ligand was permuted in the series ammonia > dimethylamine > 4-aminopyridine > 4-aminoquinoline > tacrine. Calculated desolvation free energies of the optimum dimers match the trend in IC50 values, suggesting the importance of ligand h...
To provide a further test of the dual binding site hypothesis proposed for acetylcholinesterase (ACh...
Investigation of acetylcholinesterase (AChE) inhibition potency of some new Schiff base derivatives ...
The general procedure of neurochemical characterization of memory enhancing properties of novel dime...
Tacrine (THA) is approved by the FDA for the palliative treatment of Alzheimer's disease, but its us...
Three series of 4-aminopyridine-and 4-aminoquinoline based symmetrical bivalent acetylcholinesterase...
Based upon synthetic and biochemical results, a novel and potent tacrine analogue and heterobivalent...
Tacrine (THA), as the first approved acetylcholinesterase (AChE) inhibitors for the treatment of Alz...
Tacrine-based AChE and BuChE inhibitors were designed by investigating the topology of the active si...
Two novel families of dual binding site acetylcholinesterase (AChE) inhibitors have been developed, ...
At present the only FDA-approved therapy for Alzheimer's disease involves the administration of...
Acetylcholinesterase (AChE) is an essential enzyme that terminates cholinergic transmission by rapid...
Acetylcholinesterase (AChE) is an essential enzyme that terminates cholinergic transmission by rapid...
Tacrine heterobivalent ligands were designed as novel and reversible inhibitors of cholinesterases. ...
Alzheimer's Disease (AD) is threatening about 15 million people in 1994 and the number is set to ris...
Two acetylcholinesterase (AChE) inhibitors structurally related to Tacrine, 6-methoxytacrine (1a) an...
To provide a further test of the dual binding site hypothesis proposed for acetylcholinesterase (ACh...
Investigation of acetylcholinesterase (AChE) inhibition potency of some new Schiff base derivatives ...
The general procedure of neurochemical characterization of memory enhancing properties of novel dime...
Tacrine (THA) is approved by the FDA for the palliative treatment of Alzheimer's disease, but its us...
Three series of 4-aminopyridine-and 4-aminoquinoline based symmetrical bivalent acetylcholinesterase...
Based upon synthetic and biochemical results, a novel and potent tacrine analogue and heterobivalent...
Tacrine (THA), as the first approved acetylcholinesterase (AChE) inhibitors for the treatment of Alz...
Tacrine-based AChE and BuChE inhibitors were designed by investigating the topology of the active si...
Two novel families of dual binding site acetylcholinesterase (AChE) inhibitors have been developed, ...
At present the only FDA-approved therapy for Alzheimer's disease involves the administration of...
Acetylcholinesterase (AChE) is an essential enzyme that terminates cholinergic transmission by rapid...
Acetylcholinesterase (AChE) is an essential enzyme that terminates cholinergic transmission by rapid...
Tacrine heterobivalent ligands were designed as novel and reversible inhibitors of cholinesterases. ...
Alzheimer's Disease (AD) is threatening about 15 million people in 1994 and the number is set to ris...
Two acetylcholinesterase (AChE) inhibitors structurally related to Tacrine, 6-methoxytacrine (1a) an...
To provide a further test of the dual binding site hypothesis proposed for acetylcholinesterase (ACh...
Investigation of acetylcholinesterase (AChE) inhibition potency of some new Schiff base derivatives ...
The general procedure of neurochemical characterization of memory enhancing properties of novel dime...